March 2026 in “The Journal of Dermatology” This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.
1 citations
,
September 2020 in “Selçuk tıp dergisi/Selçuk Üniversitesi Tıp Fakültesi dergisi” This review explores the current applications and expanding indications of platelet-rich plasma in dermatology and cosmetic dermatology, but reports no new clinical results.
January 2026 in “Dermatology Online Journal” This study analyzed the cost-effectiveness of scalp cooling as a means of preventing chemotherapy-induced hair loss and found it to be financially reasonable compared to dermatologic management strategies, suggesting that it should be considered for routine insurance coverage due to its cost-effectiveness.
April 2011 in “The Journal of Urology” This study concluded that finasteride is most cost-effective for prostate cancer chemoprevention when started at age 65 and continued until age 80.
December 2021 in “Cureus” This study found that for managing early-onset androgenetic alopecia in men, minoxidil monotherapy is cost-effective at a $50,000 willingness-to-pay threshold, while combining minoxidil with platelet-rich plasma becomes cost-effective at a $100,000 threshold.